7.72  0.08 (1.05%)		04-24 16:00
Open: 7.67 High: 7.845 Volume: 144,270		Pre. Close: 7.64 Low: 7.435 Market Cap: 203(M)

Short term
Mid term
Targets	6-month :	10.06	1-year :	11.49
Resists	First :	8.61	Second :	9.84
Pivot price	7.71
Supports	First :	6.64	Second :	5.52
MAs	MA(5) :	7.63	MA(20) :	8.05
	MA(100) :	7.61	MA(250) :	7.71
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	41	D(3) :	36.4
RSI	RSI(14): 47.6
52-week	High :	11.3	Low :	4.29

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CVRX ] has closed below upper band by 50.0%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.85 - 7.89	7.89 - 7.92
Low:	7.34 - 7.38	7.38 - 7.42
Close:	7.65 - 7.72	7.72 - 7.78

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Thu, 23 Apr 2026
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN

Wed, 22 Apr 2026
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mon, 20 Apr 2026
CVRx nominates Michael Dale to board of directors - Investing.com

Mon, 20 Apr 2026
Former Abbott structural heart leader Michael Dale lands CVRx board nomination - Stock Titan

Mon, 20 Apr 2026
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - Yahoo Finance

Mon, 20 Apr 2026
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	26 (M)
Shares Float	18 (M)
Held by Insiders	9.3 (%)
Held by Institutions	66.1 (%)
Shares Short	1,690 (K)
Shares Short P.Month	1,930 (K)

EPS	-2.04
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	-94.1 %
Operating Margin	-69.9 %
Return on Assets (ttm)	-26.9 %
Return on Equity (ttm)	-96.6 %
Qtrly Rev. Growth	4.4 %
Gross Profit (p.s.)	1.83
Sales Per Share	2.15
EBITDA (p.s.)	-1.92
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-24 (M)

PE Ratio	-3.79
PEG Ratio	0
Price to Book value	5.14
Price to Sales	3.58
Price to Cash Flow	-5.06

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.